COMBINATION TREATMENTS COMPRISING PROTEASE BINDING PROTEINS FOR INFLAMMATORY DISORDERS
Provided are methods and compositions for using protease binding proteins in combination with other therapeutic agents to treat inflammatory disorders such as rheumatoid arthritis, psoriasis, multiple sclerosis, systemic sclerosis, asthma, chronic obstructive pulmonary disease, inflammatory bowel disease (e.g., Crohn's and ulcerative colitis). The use of the protease binding protein allows a lower dose of the other therapeutic agents to be used in the methods and compositions, such that side effects of the other therapeutic agents are reduced or removed.
1 . A method of treating an inflammatory disorder, the method comprising:
administering a therapeutically effective amount of a protease binding protein in combination with a therapeutically effective amount of a second agent, wherein the second agent is an agent for the treatment of the inflammatory disorder,
to a subject having or suspected of having the inflammatory disorder.
2 . The method of claim 1 , wherein the inflammatory disorder is selected from the group consisting of: rheumatoid arthritis, psoriasis, multiple sclerosis, systemic sclerosis, asthma, chronic obstructive pulmonary disease, and inflammatory bowel disease.
3 . The method of claim 1 , wherein the protease binding protein is a protease inhibitor.
4 . The method of claim 1 , wherein the protease binding protein binds to a protease selected from the group consisting of: MMP-14, plasma kallikrein, plasmin, MMP-9, MMP-9/-2, and MMP-12.
5 . The method of claim 1 , wherein the protease binding protein is an MMP-14 binding protein.
6 . The method of claim 5 , wherein the MMP-14 binding protein comprises the 3 heavy chain CDRs and/or the 3 light chain CDRs of DX-2400, DX-2410, M0031-C02, M0031-F01, M0033-H07, M0037-009, M0037-D01, M0038-E06, M0038-F01, M0038-F08, M0039-H08, M0040-A06, M0040-A11, or M0043-G02.
7 . The method of claim 5 , wherein the MMP-14 binding protein comprises the heavy chain variable region and/or the light chain variable region of DX-2400, DX-2410, M0031-C02, M0031-F01, M0033-H07, M0037-009, M0037-D01, M0038-E06, M0038-F01, M0038-F08, M0039-H08, M0040-A06, M0040-A11, or M0043-G02.
8 . The method of claim 5 , wherein the MMP-14 binding protein comprises the 3 heavy chain CDRs and/or the 3 light chain CDRs of DX-2400.
9 . The method of claim 5 , wherein the MMP-14 binding protein comprises the heavy chain variable region and/or the light chain variable region of DX-2400.
10 . The method of claim 1 , wherein the protease binding protein is an inhibitor of plasma kallikrein.
11 . The method of claim 10 , wherein the inhibitor of plasma kallikrein is selected from the group consisting of: a Kunitz domain containing polypeptide and a plasma kallikrein binding antibody.
12 . The method of claim 10 , wherein the inhibitor of plasma kallikrein is a Kunitz domain containing polypeptide that comprises the sequence:
Xaa1 Xaa2 Xaa3 Xaa4 Cys Xaa6 Xaa7 Xaa8 Xaa9 Xaa10 Xaa11 Gly Xaa13 Cys Xaa15 Xaa16 Xaa17 Xaa18 Xaa19 Xaa20 Xaa21 Xaa72 Xaa23 Xaa24 Xaa25 Xaa26 Xaa27 Xaa28 Xaa29 Cys Xaa31 Xaa32 Phe Xaa34 Xaa35 Gly Gly Cys Xaa39 Xaa40 Xaa41 Xaa42 Xaa43 Xaa44 Xaa45 Xaa46 Xaa47 Xaa48 Xaa49 Xaa50 Cys Xaa52 Xaa53 Xaa54 Cys Xaa56 Xaa57 Xaa58 (SEQ ID NO:1), wherein
Xaa10 is Asp or Glu; Xaa11 is Asp, Gly, Ser, Val, Asn, Ile, Ala or Thr; Xaa13 is Pro, Arg, His, Asn, Ser, Thr, Ala, Gly, Lys or Gln; Xaa15 is Arg, Lys, Ala, Ser, Gly, Met, Asn or Gln; Xaa16 is Ala, Gly, Ser, Asp or Asn; Xaa17 is Ala, Asn, Ser, Ile, Gly, Val, Gln or Thr; Xaa18 is His, Leu, Gln or Ala; Xaa19 is Pro, Gln, Leu, Asn or Ile; Xaa21 is Trp, Phe, Tyr, His or Be; Xaa31 is Glu, Asp, Gln, Asn, Ser, Ala, Val, Leu, Be or Thr; Xaa32 is Glu, Gln, Asp Asn, Pro, Thr, Leu, Ser, Ala, Gly or Val; Xaa34 is Be, Thr, Ser, Val, Ala, Asn, Gly or Leu; Xaa35 is Tyr, Trp or Phe; Xaa39 is Glu, Gly, Ala, Ser or Asp; amino acids Xaa6, Xaa7, Xaa8, Xaa9, Xaa20, Xaa24, Xaa25, Xaa26, Xaa27, Xaa28, Xaa29, Xaa41, Xaa42, Xaa44, Xaa46, Xaa47, Xaa48, Xaa49, Xaa50, Xaa52, Xaa53 and Xaa54 is any amino acid; each of the first four and at last three amino acids of SEQ ID NO:1 can each individually optionally be present or absent and is any non-cysteine amino acid.
13 . The method of claim 10 , wherein the inhibitor of plasma kallikrein is a Kunitz domain containing polypeptide that comprises the sequence of amino acids 3-60 of SEQ ID NO:2.
14 . The method of claim 10 , wherein the inhibitor of plasma kallikrein is a Kunitz domain containing polypeptide that consists of the sequence of amino acids 3-60 of SEQ ID NO:2.
15 . The method of claim 10 , wherein the inhibitor of plasma kallikrein is a Kunitz domain containing polypeptide that comprises the sequence of SEQ ID NO:2.
16 . The method of claim 10 , wherein the inhibitor of plasma kallikrein is a Kunitz domain containing polypeptide that consists of the sequence of SEQ ID NO:2.
17 . The method of claim 1 , wherein the protease binding protein is an inhibitor of plasmin.
18 . The method of claim 17 , wherein the inhibitor of plasmin is selected from the group consisting of: a Kunitz domain containing polypeptide and a plasmin binding antibody.
19 . The method of claim 17 , wherein the inhibitor of plasmin is a Kunitz domain containing polypeptide that comprises the sequence:
Xaa1-Xaa2-Xaa3-Xaa4-Cys-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Gly-Xaa13-Cys-Xaa15-Xaa16Xaa17-Xaa18-Xaa 19-Arg-Xaa21-Xaa72-Xaa23-Xaa24-Xaa25-Xaa26-Xaa27-Xaa28-Xaa29-Cys-Xaa31-Xaa 32-Phe-Xaa34-Xaa35-Xaa36-Gly-Cys-Xaa39-Xaa40-Xaa41-Xaa42-Xaa43-Xaa44-Xaa45-Xaa46-Xaa47-Xaa48-Xaa49-Xaa50-Cys-Xaa52-Xaa53-Xaa54-Cys-Xaa56-Xaa57-Xaa58 (SEQ ID NO:300), wherein
Xaa1, Xaa2, Xaa3, Xaa4, Xaa56, Xaa57 and Xaa58 may each individually be absent; Xaa10 is Asp, Glu, Tyr, or Gln; Xaal 1 is Thr, Ala, Ser, Val or Asp; Xaa13 is Pro, Leu or Ala; Xaa15 is Lys or Arg; Xaa16 is Ala or Gly; Xaa17 is Arg, Lys or Ser; Xaa18 is Phe or Ile; Xaa19 is Glu, Gln, Asp, Pro, Gly, Ser or Ile; Xaa21 is Phe, Tyr or Trp; Xaa22 is Tyr or Phe. Xaa23 is Tyr or Phe; Xaa31 is Asp, Glu, Thr, Val, Gln or Ala; Xaa32 is Thr, Ala, Glu, Pro, or Gln; Xaa34 is Val, Ile, Thr, Leu, Phe, Tyr, His, Asp, Ala, or Ser; Xaa35 is Tyr or Tip; Xaa36 is Gly or Ser; Xaa39 is Glu, Gly, Asp, Arg, Ala, Gln, Leu, Lys, or Met; Xaa40 is Gly or Ala; Xaa43 is Asn or Gly; or Xaa45 is Phe or Tyr; and where not specified, Xaa is any non-cysteine amino acid.
20 . The method of claim 17 , wherein the inhibitor of plasmin is a Kunitz domain containing polypeptide that comprises the sequence of SEQ ID NO:100.
21 . The method of claim 17 , wherein the inhibitor of plasmin is a Kunitz domain containing polypeptide that consists of the sequence of SEQ ID NO:100.
22 . The method of claim 17 , wherein the inhibitor of plasmin is a Kunitz domain containing polypeptide that comprises the sequence of SEQ ID NO:200.
23 . The method of claim 17 , wherein the inhibitor of plasmin is a Kunitz domain containing polypeptide that consists of the sequence of SEQ ID NO:200.
24 . The method of claim 1 , wherein the protease binding protein is an MMP-9 binding protein.
25 . The method of claim 24 , wherein the MMP-9 binding protein comprises the 3 heavy chain CDRs and/or the 3 light chain CDRs of DX-2802, 539A-M0240-B03, M0078-G07, M0081-D05, M0076-D03, M0072-H07, M0075-D12, M0166-F10, M0279-A03, M0279-B02, M0288-008, or M0281-F06.
26 . The method of claim 24 , wherein the MMP-9 binding protein comprises the heavy chain variable region and/or the light chain variable region of DX-2802, 539A-M0240-B03, M0078-G07, M0081-D05, M0076-D03, M0072-H07, M0075-D12, M0166-F10, M0279-A03, M0279-B02, M0288-008, or M0281-F06.
27 . The method of claim 24 , wherein the MMP-9 binding protein comprises the 3 heavy chain CDRs and/or the 3 light chain CDRs of DX-2802.
28 . The method of claim 24 , wherein the MMP-9 binding protein comprises the heavy chain variable region and/or the light chain variable region of DX-2802.
29 . The method of claim 1 , wherein the protease binding protein is an MMP-9/-2 binding protein.
30 . The method of claim 29 , wherein the MMP-9/-2 binding protein comprises the 3 heavy chain CDRs and/or the 3 light chain CDRs of M0237-D02, X0106-A01, X0106-B02, X0106-004, X0106-E4, or X0106-F05.
31 . The method of claim 29 , wherein the MMP-9/-2 binding protein comprises the heavy chain variable region and/or the light chain variable region of M0237-D02, X0106-A01, X0106-B02, X0106-004, X0106-E4, or X0106-F05.
32 . The method of claim 29 , wherein the MMP-9/-2 binding protein comprises the 3 heavy chain CDRs and/or the 3 light chain CDRs of M0237-D02.
33 . The method of claim 29 , wherein the MMP-9/-2 binding protein comprises the heavy chain variable region and/or the light chain variable region of M0237-D02.
34 . The method of claim 1 , wherein the protease binding protein is an MMP-12 binding protein.
35 . The method of claim 34 , wherein the MMP-12 binding protein comprises the 3 heavy chain CDRs and/or the 3 light chain CDRs of DX-2712, a mutant or variant of DX-2712, 539B-X0041-D02, M0134-A02, M134-A05, M134-A07, M134-A09, M134-A10, M134-A11, M0134-B01, M134-B04, M0134-B08, M0134-B11, M0134-001, M0134-C02, M0134-006, M0134-009, M0134-C10, M0134-C11, M0134-C12, M0134-D02, M0134-D03, M0134-E04, M0134-E07, M0134-E08, M134-E11, M0134-F01, M0134-F05, M0134-G02, M0134-004, M0134-G07, M0135-A03, M0135-A05, M0135-A06, M0135-A07, M0135-B02, M0135-B08, M0135-001, M0135-C11, M0135-E03, M0135-F03, M0135-F11, M0135-G02, M0135-G03, M0135-G07, M0135-G11, M0135-H03, M0135-H10, M0105-C05, M0105-E11, M0105-F08, M0107-A12, M0108-A02, M0109-G11, M0110-G05, M0129-B11, M0130-A01, M0130-C12, M0130-F06, M0130-H04, M0131-A06, M0131-D03, M0132-A04, M0133-B08, M0133-E05, M0121-E07, M0118-F11, M0125-G07, M0124-E07, M0119-D01, M0119-A02, M0122-006, M0123-G07, M0063-A02, M0063-A04, M0063-B01, M0063-B11, M0063-007, M0063-G01, M0065-E12, M0065-003, M0065-H05, M0067-A02, M0067-B06, M0067-B09, M0067-C10, M0067-F02, M0067-F06, M0069-A04, M0069-A11, M0069-C02, M0069-D10, M0069-007, M0071-A01, M0071-B07, M0071-D05, M0071-D09, M0071-H03, M0071-H06, M0087-F09, M0088-F07, M0088-G10, M0088-H10, M0089-001, M0089-F05, M0089-B07, M0089-H11, M0032-E01, M0034-004, M0039-F01, M0041-B05, M0041-G01, M0042-B06, M0006-B10, M0007-H06, M0008-H09, M00094108, M0011-H11, M0015-F02, M0016-D01, M0013-D11, M0013-G12, M0013-H06, M0014-009, M0014-G11, M0016-A11, M0016-H05, M0019-C05, M0020-B01, M0022-007, M0025-D04, M0027-E11, 539B-X0041-D02, 539B-X0049-A01, 539B-X0049-B01, 539B-X0049-C01, 539B-X0049-D01, 539B-X0049-E01, 539B-X0049-F01, 539B-X0049-G01, 539B-X0049-H01, 539B-X0049-A02, 539B-X0049-B02, 539B-X0049-C02, 539B-X0049-D02, or 539B-X0049-E02.
36 . The method of claim 34 , wherein the MMP-12 binding protein comprises the heavy chain variable region and/or the light chain variable region of DX-2712, a mutant or variant of DX-2712, 539B-X0041-D02, M0134-A02, M134-A05, M134-A07, M134-A09, M134-A10, M134-A11, M0134-B01, M134-B04, M0134-B08, M0134-B11, M0134-001, M0134-C02, M0134-006, M0134-009, M0134-C10, M0134-C11, M0134-C12, M0134-D02, M0134-D03, M0134-E04, M0134-E07, M0134-E08, M134-E11, M0134-F01, M0134-F05, M0134-G02, M0134-G04, M0134-G07, M0135-A03, M0135-A05, M0135-A06, M0135-A07, M0135-B02, M0135-B08, M0135-001, M0135-C11, M0135-E03, M0135-F03, M0135-F11, M0135-G02, M0135-G03, M0135-G07, M0135-G11, M0135-H03, M0135-H10, M0105-C05, M0105-E11, M0105-F08, M0107-A12, M0108-A02, M0109-G11, M0110-G05, M0129-B11, M0130-A01, M0130-C12, M0130-F06, M0130-H04, M0131-A06, M0131-D03, M0132-A04, M0133-B08, M0133-E05, M0121-E07, M0118-F11, M0125-G07, M0124-E07, M0119-D01, M0119-A02, M0122-C06, M0123-G07, M0063-A02, M0063-A04, M0063-B01, M0063-B11, M0063-007, M0063-G01, M0065-E12, M0065-G03, M0065-H05, M0067-A02, M0067-B06, M0067-B09, M0067-C10, M0067-F02, M0067-F06, M0069-A04, M0069-A11, M0069-C02, M0069-D10, M0069-G07, M0071-A01, M0071-B07, M007′-D05, M0071-D09, M0071-H03, M0071-H06, M0087-F09, M0088-F07, M0088-G10, M0088-H10, M0089-001, M0089-F05, M0089-B07, M0089-H11, m0032-E01, M0034-004, M0039-F01, M0041-B05, M0041-601, M0042-B06, M0006-B10, M0007-H06, M0008-H09, M0009-H08, M0011-H11, M0015-F02, M0016-D01, M0013-D11, M0013-G12, M0013-H06, M0014-009, M0014-G11, M0016-A11, M0016-H05, M0019-C05, M0020-B01, M0022-007, M0025-D04, M0027-E11, 539B-X0041-D02, 539B-X0049-A01, 539B-X0049-B01, 539B-X0049-001, 539B-X0049-D01, 539B-X0049-E01, 539B-X0049-F01, 539B-X0049-G01, 539B-X0049-H01, 539B-X0049-A02, 539B-X0049-B02, 539B-X0049-C02, 539B-X0049-D02, or 539B-X0049-E02.
37 . The method of claim 34 , wherein the MMP-12 binding protein comprises the 3 heavy chain CDRs and/or the 3 light chain CDRs of DX-2712.
38 . The method of claim 34 , wherein the MMP-12 binding protein comprises the heavy chain variable region and/or the light chain variable region of DX-2712.
39 . The method of claim 1 , wherein the second agent is an immunosuppressant agent selected from the group consisting of: gancyclovir, etanercept, cyclosporine, tacrolimus, rapamycin, cyclophosphamide, azathioprine, mycophenolate mofetil, methotrexate, cortisol, aldosterone, dexamethasone, a cyclooxygenase inhibitor, a 5-lipoxygenase inhibitor, and leukotriene receptor antagonist.
40 . The method of claim 1 , wherein the second agent is an agent for the treatment of an inflammatory disorder selected from the group of inflammatory disorders consisting of: rheumatoid arthritis, psoriasis, multiple sclerosis, systemic sclerosis, asthma, chronic obstructive pulmonary disease, and inflammatory bowel disease.
41 . The method of claim 40 , wherein the second agent is an agent for the treatment of rheumatoid arthritis and comprises a nonsteroidal anti-inflammatory drug (NSAID), a corticosteroid, a Disease-Modifying Antirheumatic Drug (DMARD), or a biological response modifier (BRM).
42 . The method of claim 40 , wherein the second agent is an agent for the treatment of rheumatoid arthritis and comprises aspirin, naproxen, ibuprofen, etodolac, gold, salsalte, methotrexate, sulfasalazine, D-penicillamine, azathioprine, cyclophosphamide, chlorambucil, cyclosporine, leflunomide, etanercept, infliximab, anakinra, adalimumab, hydroxychloroquine, chloroquine phosphate, chloroquine sulphate, minocycline, or a CTLA4-Ig.
43 . The method of claim 40 , wherein the second agent is an agent for the treatment of psoriasis and comprises a topical treatment or a systemic treatment.
44 . The method of claim 40 , wherein the second agent is an agent for the treatment of psoriasis and comprises a topical treatment selected from the group consisting of coal tar, dithranol, a corticosteroid, a vitamin D3 analogue, and a retinoid.
45 . The method of claim 40 , wherein the second agent is an agent for the treatment of psoriasis and comprises a systemic treatment selected from the group consisting of methotrexate, cyclosporine, a retinoid, tioguanine, hydroxyurea, sulfasalazine, mycophenolate mofetil, azathioprine, tacrolimus, alefacept, efalizumab, etanercept, and infliximab.
46 . The method of claim 40 , wherein the second agent is an agent for the treatment of multiple sclerosis and comprises a corticosteroid, an interferon, glatiramer acetate, an immunosuppressant or natalizumab.
47 . The method of claim 40 , wherein the second agent is an agent for the treatment of systemic sclerosis and comprises an NSAID, a calcium channel blocker, prostacyclin analogue, a dual endothelin-receptor antagonist, methotrexate, cyclosporin, an ACE inhibitor, cyclophosphamide, a steroid, or epoprostenol.
48 . The method of claim 40 , wherein the second agent is an agent for the treatment of systemic sclerosis and comprises nifedipine.
49 . The method of claim 40 , wherein the second agent is an agent for the treatment of systemic sclerosis and comprises iloprost.
50 . The method of claim 40 , wherein the second agent is an agent for the treatment of systemic sclerosis and comprises bosentan.
51 . The method of claim 40 , wherein the second agent is an agent for the treatment of asthma and comprises a glucocorticoid, a leukotriene modifier, a mast cell stabilizer, an antimuscarinic/anticholinergic, an antihistamines, an IgE blocker, or methotrexate.
52 . The method of claim 40 , wherein the second agent is an agent for the treatment of asthma and comprises a beta 2 -adrenoceptor agonist selected from the group consisting of: salbutamol, levalbuterol, terbutaline and bitolterol.
53 . The method of claim 40 , wherein the second agent is an agent for the treatment of asthma and comprises an adrenergic agonist selected from the group consisting of: inhaled epinephrine and ephedrine tablets.
54 . The method of claim 40 , wherein the second agent is an agent for the treatment of asthma and comprises an antimuscarinic/anticholinergic selected from the group consisting of: ipratropium, oxitropium, and tiotropium.
55 . The method of claim 40 , wherein the second agent is an agent for the treatment of asthma and comprises an inhaled glucocorticoid selected from the group consisting of: ciclesonide, beclomethasone, budesonide, flunisolide, fluticasone, mometasone, and triamcinolone.
56 . The method of claim 40 , wherein the second agent is an agent for the treatment of asthma and comprises a leukotriene modifier selected from the group consisting of: montelukast, zafirlukast, pranlukast, and zileuton.
57 . The method of claim 40 , wherein the second agent is an agent for the treatment of asthma and comprises a mast cell stabilizer selected from the group consisting of: cromoglicate and nedocromil.
58 . The method of claim 40 , wherein the second agent is an agent for the treatment of asthma and comprises a methylxanthine selected from the group consisting of: theophylline and aminophylline.
59 . The method of claim 40 , wherein the second agent is an agent for the treatment of asthma and comprises an antihistamine.
60 . The method of claim 40 , wherein the second agent is an agent for the treatment of asthma and comprises an IgE blocker selected from the group consisting of: omalizumab and methotrexate.
61 . The method of claim 40 , wherein the second agent is an agent for the treatment of asthma and comprises a long-acting beta 2 -adrenoceptor agonist selected from the group consisting of: salmeterol, formoterol, bambuterol, and albuterol.
62 . The method of claim 40 , wherein the second agent is an agent for the treatment of asthma and comprises a combination of inhaled steroid and a long-acting bronchodilator selected from the group consisting of: fluticasone/salmeterol and budesonide/formoterol.
63 . The method of claim 40 , wherein the second agent is an agent for the treatment of chronic obstructive pulmonary disease (COPD) and comprises a bronchodilator.
64 . The method of claim 40 , wherein the second agent is an agent for the treatment of chronic obstructive pulmonary disease (COPD) and comprises a β 2 agonist, an M 3 antimuscarinic, a leukotriene antagonist, a cromone, a corticosteroid, or a xanthine.
65 . The method of claim 40 , wherein the second agent is an agent for the treatment of chronic obstructive pulmonary disease (COPD) and comprises a β 2 agonist selected from the group consisting of: Salbutamol, Bambuterol, Clenbuterol, Fenoterol, Formoterol, and Salmeterol.
66 . The method of claim 40 , wherein the second agent is an agent for the treatment of chronic obstructive pulmonary disease (COPD) and comprises the Ipratropium.
67 . The method of claim 40 , wherein the second agent is an agent for the treatment of chronic obstructive pulmonary disease (COPD) and comprises a cromone selected from the group consisting of: Cromoglicate and Nedocromil.
68 . The method of claim 40 , wherein the second agent is an agent for the treatment of chronic obstructive pulmonary disease (COPD) and comprises a leukotriene antagonist selected from the group consisting of: Montelukast, Pranlukast, and Zafirlukast.
69 . The method of claim 40 , wherein the second agent is an agent for the treatment of chronic obstructive pulmonary disease (COPD) and comprises a corticosteroid antagonist selected from the group consisting of: glucocorticoids, beclomethasone, mometasone, and fluticasone.
70 . The method of claim 40 , wherein the second agent is an agent for the treatment of chronic obstructive pulmonary disease (COPD) and comprises a xanthine antagonist selected from the group consisting of: theophylline, methylxanthine, and theobromine.
71 . The method of claim 40 , wherein the second agent is an agent for the treatment of chronic obstructive pulmonary disease (COPD) and comprises Ipratropium or Tiotropium.
72 . The method of claim 40 , wherein the second agent is an agent for the treatment of inflammatory bowel disease and comprises an immunosuppresant, an anti-TNF binding protein, a cytokine inhibitor, a BRM, or an anti-inflammatory.
73 . The method of claim 40 , wherein the second agent is an agent for the treatment of inflammatory bowel disease and comprises prednisone, infliximab, azathioprine, methotrexate, 6-mercaptopurine , a mesalamine, a steroid, or CDP571 antibody.
74 . A method of preventing an inflammatory disorder, the method comprising:
administering a therapeutically effective amount of a protease binding protein in combination with a therapeutically effective amount of a second agent, wherein the second agent is an agent for the treatment of the inflammatory disorder,
to a subject at risk of having the inflammatory disorder.
75 . A composition comprising a protease binding protein and a second agent, wherein the second agent is an agent for the treatment of an inflammatory disorder.
76 . A kit comprising a protease binding protein and a second agent, wherein the second agent is an agent for the treatment of an inflammatory disorder.